Mild or moderate COVID-19 or seasonal influenza infection Infections and Infestations
Conditions
Interventions
Eligible participants were assigned in a 1:1 ratio to receive either the ACF formulation (ammonium chloride 500 mg + vitamin D 2000 IU) or the VDF formulation (vitamin D 2000 IU only).
Assignment was
the blinding code was held solely by the manufacturer and disclosed only after completion of enrolment and data collection.
Both formulations were enteric-coated, sustained-release tablets administere
Sponsors
National and Kapodistrian University of Athens
Eligibility
Sex/Gender
All
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: Laboratory testing verified SARS-CoV-2 or Influenza A or Influenza B infection
Exclusion criteria
Exclusion criteria: 1. Age <18 years 2. Pregnancy or lactation 3. Denial of informed consent 4. Known allergy to study components 5. Organ transplantation 6. Frailty score =5
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reduction of viral load, measured using RT-PCR cycle threshold (Ct) values obtained at baseline (Day 1), Day 3–5, and Day 10–12 | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Duration and severity of symptoms for 30 days documented through structured symptom diary and investigator follow-up at Day 30 2. Incidence of hospitalization (for outpatients) confirmed through clinical charts and hospital admission logs within 30 days of enrolment 3. Need for oxygen supplementation confirmed through clinical charts and hospital admission logs within 30 days of enrolment 4. ICU admission confirmed through clinical charts and hospital admission logs within 30 days of enrolment 5. Intubation confirmed through clinical charts and hospital admission logs within 30 days of enrolment 6. Death verified via hospital documentation, within 30 days of enrolment | — |
Countries
Greece
Contacts
Public ContactNikolaos Drakoulis
Outcome results
None listed